Women veterans who served in Iraq, Afghanistan, and other locations with toxic exposures face a breast cancer risk that research increasingly links to the chemical environment of modern military service. The PACT Act of 2022 recognized this connection, adding breast cancer to VA's list of presumptive cancers for veterans with qualifying toxic exposures. This guide is written with care for the experience of women veterans — navigating a cancer diagnosis, an often bewildering benefits system, and the particular challenges of a VA system that was not always designed with women's health in mind. Your service earned these benefits. Here's how to access them.
A Note on This Guide
Breast cancer is a deeply personal diagnosis. This guide provides factual, practical information about VA benefits — rating criteria, claim procedures, legal pathways. We've aimed for straightforward language that respects the complexity of what you're going through. If any section feels too clinical or misses your experience, know that your individual claim deserves individualized support from a VA-accredited representative who understands women veterans' health.
The PACT Act (Sergeant First Class Heath Robinson Honoring our Promise to Address Comprehensive Toxics Act, 2022) added breast cancer to VA's presumptive conditions list for veterans with qualifying toxic exposures. This means that if you served at a covered location and have been diagnosed with breast cancer, VA presumes the cancer is related to your service — no nexus letter is required, and you don't need to prove which specific chemical caused your cancer.
The scientific basis for including breast cancer in the PACT Act draws on research linking several classes of military exposures to breast cancer risk:
Polycyclic aromatic hydrocarbons (PAHs) in burn pit smoke — known mammary gland carcinogens in animal models with supportive human epidemiological data
Benzene — a well-established carcinogen with evidence of breast cancer association in occupational exposures
Dioxins and dioxin-like compounds in herbicide agents and combustion byproducts — associated with breast cancer risk in multiple studies
Jet fuels and solvents (JP-8, benzene, toluene) — routine exposure for aviation, motor transport, and maintenance personnel
Ionizing radiation — known breast carcinogen, particularly relevant for atomic veterans
PACT Act Benefit: No Nexus Letter Required
For qualifying PACT Act breast cancer claims, you do not need a private medical opinion linking your cancer to your service. The law itself creates the presumption. Your deployment records plus your cancer diagnosis are the evidence. This significantly reduces both the complexity and the burden of filing — you do not need to navigate the nexus letter process.
Who Qualifies: Service Requirements
PACT Act breast cancer coverage requires service at a covered location with qualifying toxic exposure:
Covered Locations
Southwest Asia after August 2, 1990: Iraq, Kuwait, Saudi Arabia, Qatar, Bahrain, UAE, Oman, Jordan, Egypt
Afghanistan, Djibouti, Somalia, Syria — after September 11, 2001
Karshi-Khanabad (K2), Uzbekistan — October 2001 through December 2005
Other locations designated by the Secretary of Defense
Discharge Requirement
Your discharge must be under conditions other than dishonorable. The vast majority of military discharges — honorable, general under honorable conditions, medical — qualify. If you have questions about your specific discharge status, a VA-accredited attorney can advise you.
Additional Pathways Beyond PACT Act
If you served in covered locations and have breast cancer, the PACT Act is the primary pathway. However, other pathways exist for veterans who don't meet PACT Act criteria:
Ionizing radiation presumptive (38 CFR § 3.309(d)): Atomic veterans, Operation Tomodachi participants, and others with documented radiation exposure — breast cancer is included
Direct service connection: With a nexus letter linking breast cancer to a specific in-service exposure, even without PACT Act qualifying service
DC 7626/7627/7628: How VA Rates Breast Cancer
VA uses several diagnostic codes for breast cancer and breast conditions in 38 CFR Part 4:
DC
Condition
Rating Range
7626
Malignant neoplasm of the breast
100% during treatment; residuals after
7627
Benign and other neoplasms of the breast
Based on functional impairment
7628
Gynecomastia, surgery for
Based on residuals of treatment
For active breast cancer, DC 7626 is the primary code. The rating structure follows VA's standard malignant neoplasm framework: 100% during active treatment, followed by a six-month evaluation period at 100%, then a residuals-based rating after re-evaluation.
Post-treatment residuals from breast cancer are rated under various codes depending on the type of impairment: lymphedema, limited arm range of motion, scars, cognitive effects, cardiac effects, and endocrine (hormonal) effects are each rated under the appropriate diagnostic code for that condition type.
100% Rating During Active Treatment
Active treatment for breast cancer — encompassing the wide range of treatments used in modern oncology — all qualify for the 100% rating:
Chemotherapy: Neoadjuvant or adjuvant chemotherapy regimens including AC (doxorubicin/cyclophosphamide), AC-T (with paclitaxel or docetaxel), CMF, TC, and others
Radiation therapy: Whole breast radiation, partial breast irradiation, chest wall radiation post-mastectomy, regional node radiation
Hormonal/endocrine therapy: Tamoxifen, aromatase inhibitors (anastrozole, letrozole, exemestane), ovarian suppression — these treatments are typically ongoing for 5–10 years; discuss with your claim representative whether ongoing endocrine therapy constitutes "active treatment" for rating purposes
CDK 4/6 inhibitors: Palbociclib, ribociclib, abemaciclib for hormone receptor-positive advanced breast cancer
PARP inhibitors: Olaparib, talazoparib for BRCA-mutated breast cancer
Immunotherapy: Pembrolizumab (Keytruda) for certain triple-negative breast cancers
When Does "Active Treatment" End?
This is one of the most contested questions in breast cancer VA claims. Chemotherapy and radiation have clear endpoints. But hormonal therapy (tamoxifen, aromatase inhibitors) is typically continued for 5–10 years after initial treatment. VA's position on whether ongoing endocrine therapy constitutes "active treatment" for rating purposes is not uniformly applied — some rating decisions treat endocrine therapy as active treatment (maintaining 100%), while others do not. This is an area where working with a VA-accredited attorney matters significantly.
Residuals After Treatment: What Gets Rated
After the six-month post-treatment evaluation, VA rates residual conditions from breast cancer and its treatment. Understanding what can be rated — and ensuring the C&P examiner evaluates each — is critical to receiving fair compensation:
Surgical Residuals
Mastectomy — whether lumpectomy, simple mastectomy, or modified radical mastectomy — leaves lasting effects beyond the removal of tissue. These include:
Chest wall scars: Rated under DC 7800 (disfiguring scars of the head, face, or neck) or DC 7801-7805 for other scar types, based on size, tenderness, and disfigurement
Breast tissue loss: The loss of breast tissue is rated based on the functional and anatomical impairment; in VA's framework this may be rated under the applicable scar codes or analogous conditions
Limited shoulder/arm range of motion: Post-surgical changes and radiation fibrosis can limit range of motion in the ipsilateral arm — rated under the applicable musculoskeletal codes (DC 5200 series for shoulder)
Seroma or wound complications: If chronic, these may be ratable as ongoing surgical complications
Radiation-Related Residuals
Radiation fibrosis: Scarring and stiffness from radiation to the chest wall, breast tissue, or regional lymph nodes — affects shoulder range of motion and chest wall compliance
Radiation pneumonitis / pulmonary fibrosis: From radiation to the chest wall or internal mammary nodes — rated under pulmonary codes based on pulmonary function testing
Cardiac toxicity: Left-sided radiation is associated with coronary artery disease, pericarditis, and cardiac dysfunction — rated under cardiac codes (DC 7000 series) based on cardiac function
Brachial plexopathy: Radiation damage to the brachial plexus nerve network causes arm weakness, numbness, and pain — rated under peripheral nerve codes based on severity
Chemotherapy-Related Residuals
Chemotherapy-induced peripheral neuropathy (CIPN): From taxane-based chemotherapy (paclitaxel, docetaxel) — numbness, tingling, pain in hands and feet; may be permanent; rated under peripheral nerve codes
Cognitive effects ("chemo brain"): Cognitive dysfunction from chemotherapy is real and documented; rated as a cognitive disorder or analogous condition based on functional impairment
Cardiac toxicity from anthracyclines: Doxorubicin (Adriamycin) can cause cardiomyopathy — rated under DC 7020 (cardiomyopathy) based on ejection fraction and functional limitation
Premature menopause: Chemotherapy-induced premature ovarian insufficiency causing early menopause — rated under relevant endocrine codes; also relevant to bone density and cardiovascular risk
Bone density loss / osteoporosis: From aromatase inhibitors or premature menopause — secondary condition potentially ratable under musculoskeletal codes if fractures or functional impairment results
Lymphedema: A Critical Residual to Claim
Lymphedema — persistent swelling of the arm caused by lymphatic system disruption — is one of the most common and impactful long-term effects of breast cancer treatment. It occurs when lymph nodes are removed or damaged during sentinel lymph node biopsy or axillary lymph node dissection, or after lymph node irradiation.
Lymphedema is chronic, often progressive, and can significantly affect quality of life — limiting arm function, causing chronic discomfort, requiring daily management (compression garments, manual drainage, specialized exercise), and creating recurring infection risk (cellulitis).
Lymphedema Severity
Characteristics
Approximate VA Rating Range
Mild
Intermittent swelling, manageable with compression, minimal functional limitation
10–20%
Moderate
Persistent swelling, daily compression required, some functional limitation
20–30%
Severe
Significant arm enlargement, marked functional limitation, recurrent infections
30–40%+
To document lymphedema for your VA claim, gather: limb circumference measurements (bilateral for comparison), photos documenting visible swelling, your physical therapist's lymphedema certification and treatment notes, any hospitalizations or emergency visits for cellulitis, and your compression garment prescriptions. All of these support a higher residuals rating.
Mental Health Secondary Conditions
A breast cancer diagnosis — particularly one that affects body image, sexual health, fertility, and mortality — can profoundly affect mental health. VA recognizes mental health conditions as separately ratable secondary conditions when they are caused or aggravated by a service-connected physical condition.
Veterans experiencing any of the following should discuss a secondary mental health claim with their VSO or attorney:
Depression or major depressive disorder — common during and after cancer treatment; rated under DC 9434
Anxiety disorder — scanxiety (anxiety about surveillance imaging), fear of recurrence; rated under DC 9400
Adjustment disorder — related to life changes from diagnosis and treatment
PTSD — some veterans experience PTSD symptoms related to the trauma of cancer diagnosis and treatment, particularly if treatment involved multiple painful procedures; rated under DC 9411
Sleep disturbance — related to hormonal changes from endocrine therapy (night sweats, insomnia); secondary to service-connected breast cancer treatment
You Don't Have to Minimize
VA's C&P process can feel impersonal. Examiners sometimes focus on physical measurements and miss the full human impact of breast cancer. You are allowed to describe the emotional, psychological, relational, and identity impacts of your diagnosis and treatment. These matter for rating purposes — and they matter because they are part of your experience. Don't minimize your suffering in an attempt to appear "fine." The C&P exam is the one context where full honesty about impact is exactly what's needed.
Your C&P Exam: Rights and Preparation
The Compensation and Pension (C&P) exam is where VA evaluates the current severity of your conditions. For breast cancer residuals, preparation and knowing your rights significantly affect outcomes.
Your Rights at the C&P Exam
Request a same-gender examiner: You have the right to request a female C&P examiner. Make this request in writing to your VA regional office when you are notified of the exam. This is not always guaranteed but VA is required to make reasonable efforts to accommodate.
Bring a support person: You may have a trusted person accompany you to the exam. They cannot speak for you during the examination, but their presence can be supportive.
Know what's being evaluated: The examiner should evaluate all conditions you claimed — if you claimed lymphedema, shoulder range of motion, peripheral neuropathy, and depression, the examiner should address each. If any condition is not assessed, note it immediately and raise it with your VSO or attorney.
Get a copy of the exam report: You are entitled to a copy of the C&P examination report. Review it carefully for accuracy. If the examiner's findings are inconsistent with your actual condition, this can form the basis of an appeal.
Preparing for Your C&P Exam
Bring all relevant medical records: oncology notes, surgical reports, radiation therapy records, imaging, current medication list
Prepare a written statement describing your worst symptoms on a typical bad day — not just how you feel at the exam
Describe every limitation: what can't you do that you could before? Work tasks? Household activities? Exercise? Social engagement?
Document all residuals: arm swelling, pain, range of motion limitations, cognitive changes, sleep disruption, emotional effects
Describe the impact on your relationships, daily functioning, and sense of self — these are relevant to mental health secondary claims
Breast Cancer in Male Veterans
Breast cancer is significantly less common in men but does occur — and male veterans with breast cancer from qualifying service deserve the same PACT Act presumptive as their fellow veterans. The DC codes (7626 for active cancer), the rating framework (100% during treatment, residuals after), and the filing process are identical.
Male veterans with breast cancer may face additional barriers: stigma around a cancer often perceived as affecting only women, and examiners who are less familiar with male breast cancer presentations. Document your diagnosis and treatment thoroughly, and don't hesitate to seek representation from a VA-accredited attorney who has experience with less common cancer claims.
How to File Your Breast Cancer Claim
Filing is the most important step — and it must happen as early as possible, because your effective date starts when VA receives your claim.
Documents to Gather
DD-214 with service dates and deployment locations
Deployment orders to PACT Act-covered location if not documented on DD-214
Pathology report confirming breast cancer type (invasive ductal, invasive lobular, triple-negative, HER2-positive, etc.)
Current medical records documenting residuals: lymphedema measurements, shoulder ROM, neuropathy evaluation, cardiac function, cognitive screening
Mental health records if applicable (psychiatry notes, counseling records)
Completed VA Form 21-526EZ
Completing Your Claim
List "Breast cancer — PACT Act presumptive due to toxic exposure during service in [location] [dates]." Then list each secondary condition separately with its relationship to the service-connected breast cancer: "Lymphedema of left arm — secondary to service-connected breast cancer (axillary node dissection)"; "Peripheral neuropathy — secondary to paclitaxel chemotherapy for service-connected breast cancer"; "Major depressive disorder — secondary to service-connected breast cancer diagnosis and treatment."
Breast cancer is PACT Act presumptive for veterans with qualifying service. Free claim review — no phone calls, no pressure. Understand your options before making any decisions.
Editorial Standards: Produced by the claim.vet Editorial Team. Verified against DC 7626 and PACT Act provisions. Content reviewed for respectful, gender-inclusive language. Last reviewed: July 2026. Not legal advice — for representation, connect with a VA-accredited attorney.
🎖️
Start Your Free VA Claim Review
Breast cancer is PACT Act presumptive. No nexus letter required. No phone calls. Understand your benefits at your own pace.